How Much Does Low-Dose Naltrexone Cost in Maryland in 2026?

Maryland Cash-Pay Pricing for LDN in 2026

The average cash-pay price for low-dose naltrexone across Maryland retail compounding pharmacies in 2026 is $50 per month for a standard 30-capsule supply. This price applies to the most common dosing range of 1.5 mg to 4.5 mg taken once nightly.

Unlike brand-name medications with published wholesale acquisition costs, LDN pricing depends on individual compounding pharmacies. The $50/month figure represents the statewide average, but prices at specific pharmacies in Baltimore, Bethesda, Annapolis, and other Maryland cities may range from $35 to $65 depending on the pharmacy's compounding volume and overhead. Pharmacies that compound LDN in high volume tend to offer lower per-capsule costs because they purchase naltrexone powder in bulk.

Standard naltrexone (50 mg tablets, FDA-approved for opioid use disorder and alcohol dependence) carries a GoodRx cash price of roughly $25 to $45 for 30 tablets at Maryland chain pharmacies [1]. Some patients and prescribers have historically split or dissolved these tablets to achieve low doses, though this approach produces inconsistent dosing. The Endocrine Society and compounding pharmacy organizations recommend professionally compounded capsules for accurate dosing at the 1.5 to 4.5 mg range [2].

Maryland Medicaid Coverage for Low-Dose Naltrexone

Maryland Medicaid covers low-dose naltrexone with prior authorization. The prior authorization requirement exists because LDN prescribing is off-label (the FDA approved naltrexone at 50 mg for substance use disorders, not at low doses for pain or autoimmune conditions).

To obtain PA approval through Maryland Medicaid, prescribers typically must document: a diagnosis of fibromyalgia, chronic pain, or a qualifying autoimmune condition; failure of at least one first-line therapy; and clinical rationale citing peer-reviewed evidence. Younger et al. demonstrated in a pilot crossover trial (N=10) that LDN 4.5 mg reduced fibromyalgia pain by 32.5% compared to placebo over 8 weeks [3]. This study, published in Pain Medicine in 2009, remains one of the most-cited references in PA submissions for LDN.

The Maryland Department of Health processes PA requests through its preferred drug program. Turnaround is typically 24 to 72 hours for standard requests. Urgent requests receive same-day review. If denied, patients have appeal rights under Maryland COMAR 10.09.03, and prescribers can submit peer-to-peer reviews with Medicaid's clinical pharmacists.

For Medicaid enrollees who receive approval, the copay is $0 to $3 depending on income tier and managed care organization.

Compounding Pharmacy Options in Maryland

LDN is legally compounded and dispensed in Maryland through licensed 503A pharmacies. These pharmacies operate under state Board of Pharmacy oversight and compound patient-specific prescriptions.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits pharmacies to compound medications for individual patients when a valid prescription exists, when the compounded drug is not essentially a copy of a commercially available product at the same strength, and when the pharmacy meets state licensing requirements [4]. Because naltrexone at 1.5 to 4.5 mg is not commercially manufactured by any FDA-approved manufacturer, 503A compounding for LDN meets all federal criteria.

Maryland has approximately 45 to 50 pharmacies with active compounding licenses. Not all compound LDN regularly. The pharmacies that specialize in LDN compounding include both independent local pharmacies in the Baltimore-Washington corridor and national mail-order compounding pharmacies licensed in Maryland. Mail-order 503A pharmacies (such as Belmar Pharmacy, Skip's Pharmacy, and others licensed to ship into MD) sometimes offer prices at or below the $50/month Maryland average due to higher compounding volumes.

Quality varies between compounding pharmacies. Patients should verify that their chosen pharmacy holds current Maryland Board of Pharmacy compounding licensure, follows USP 795 standards for non-sterile compounding, and can provide certificates of analysis for naltrexone powder sourced from FDA-registered suppliers.

Insurance Coverage Beyond Medicaid

Private insurance coverage for LDN in Maryland varies significantly by plan. Most commercial plans (CareFirst BlueCross BlueShield, Kaiser Permanente Mid-Atlantic, Aetna, Cigna, UnitedHealthcare) do not include compounded LDN on their standard formularies.

The coverage gap exists for two reasons. First, LDN has no FDA approval at low doses, so insurers classify it as off-label and non-formulary. Second, many commercial pharmacy benefit managers (PBMs) exclude compounded medications entirely from coverage. Express Scripts, CVS Caremark, and OptumRx each maintain restrictive compounding policies that limit coverage to specific categories (such as hormone replacement or dermatologic preparations) and often exclude pain or autoimmune compounded drugs.

Some Maryland patients have obtained coverage through appeals. The most successful appeals cite the growing evidence base: a 2014 systematic review identified 89 published studies on LDN across multiple conditions [5], and the Stanford fibromyalgia trial (N=31) showed a 28.8% reduction in pain scores [6]. Appeals that include a letter of medical necessity from a board-certified rheumatologist or pain specialist and documentation of failed conventional therapies have the highest approval rates.

For patients whose appeals are denied, the $50/month cash price remains accessible. This is lower than many specialty medication copays under commercial insurance.

Telehealth Access to LDN in Maryland

Maryland permits telehealth prescribing of low-dose naltrexone. The state's telehealth parity law (Maryland Code, Health-General §19-319) requires that services delivered via telehealth receive the same coverage as in-person visits when medically appropriate.

Telehealth platforms that prescribe LDN to Maryland residents include both national LDN-focused practices and general integrative medicine telehealth groups. A typical telehealth LDN consultation costs $75 to $200 for the initial visit, with follow-ups at $50 to $100. Some platforms bundle the consultation with pharmacy fulfillment, offering the visit plus a 90-day LDN supply for $175 to $250 total.

Prescribers must hold an active Maryland medical license or be registered through the Interstate Medical Licensure Compact (of which Maryland is a member state). The prescription is then sent electronically to the patient's chosen 503A compounding pharmacy, whether local or mail-order.

Dr. Jarred Younger, the researcher whose 2009 pilot trial established LDN's analgesic mechanism in fibromyalgia, has stated: "Low-dose naltrexone appears to work by transiently blocking opioid receptors, which triggers a compensatory upregulation of endorphin production and reduces microglial activation in the central nervous system" [3]. This mechanism, distinct from naltrexone's high-dose opioid antagonism, explains why the 4.5 mg dose produces anti-inflammatory effects rather than the opioid-blocking effects seen at 50 mg.

How to Get the Lowest Price for LDN in Maryland

Several strategies can reduce LDN costs below the $50/month average for Maryland patients.

Compare compounding pharmacies directly. Call three to five Maryland-licensed compounding pharmacies and request their per-capsule price for naltrexone 4.5 mg capsules, quantity 30. Prices range from $35 to $65, and a 5-minute phone call can save $15 to $20 per month.

Order 90-day supplies. Most compounding pharmacies offer a per-capsule discount for 90-capsule orders. A typical 90-day supply runs $120 to $135 (versus $150 at monthly pricing), saving 10% to 20% annually.

Use mail-order compounding pharmacies. National 503A pharmacies licensed in Maryland sometimes undercut local prices by $5 to $15 per month. Shipping is typically free or $5 flat rate.

Ask about subscription models. Some telehealth-pharmacy partnerships offer monthly subscription pricing at $40 to $45/month that includes both the prescription management and the medication.

Check patient assistance programs. While no manufacturer assistance program exists for compounded LDN (because there is no manufacturer), some compounding pharmacies offer sliding-scale pricing for uninsured patients with documented financial need.

The annual cost of LDN in Maryland, at $50/month cash pay, totals $600. This compares favorably to other chronic pain and autoimmune medications: pregabalin (Lyrica) averages $550/month without insurance, duloxetine costs $15 to $45/month generic, and biologic DMARDs like adalimumab (Humira) exceed $6,000/month at list price [7].

Clinical Evidence Supporting LDN Prescribing

Maryland prescribers writing LDN draw on a growing but still modest evidence base. The strongest data exist for fibromyalgia and Crohn's disease.

For fibromyalgia, Younger et al. (2009) conducted a double-blind, placebo-controlled crossover trial showing 32.5% pain reduction with LDN 4.5 mg versus 16.7% with placebo (P=0.016) [3]. A follow-up single-blind trial (Younger et al., 2013, N=31) confirmed these findings with daily pain diaries showing significant improvement in mechanical pain thresholds and overall symptom severity [6]. The proposed mechanism involves microglial suppression in the central nervous system, reducing neuroinflammation that drives central sensitization.

For Crohn's disease, Smith et al. (2007) published a pilot study (N=17) in the American Journal of Gastroenterology showing that 89% of patients responded to LDN 4.5 mg and 67% achieved clinical remission by 12 weeks [8]. A subsequent randomized controlled trial (Smith et al., 2011, N=34) confirmed significantly higher remission rates with LDN versus placebo [9].

The FDA has not approved naltrexone at any dose for fibromyalgia, autoimmune conditions, or chronic pain [1]. All LDN prescribing remains off-label. The American College of Rheumatology's 2016 fibromyalgia guidelines do not include LDN in their pharmacologic recommendations, though several professional societies have called for larger randomized trials.

Maryland-Specific Regulatory Considerations

Maryland's Board of Pharmacy regulates compounding under COMAR 10.34.19. Pharmacies must maintain a current compounding permit, follow USP 795 (non-sterile) or USP 797 (sterile) standards as applicable, and source active pharmaceutical ingredients from FDA-registered suppliers.

LDN capsules fall under non-sterile compounding (USP 795). Maryland does not restrict which conditions a prescriber may target with an off-label compounded medication, provided the prescriber exercises independent medical judgment and documents their clinical rationale.

The Maryland Board does not maintain a list of "approved" compounded medications. Any licensed prescriber (MD, DO, NP, or PA with prescriptive authority) may write an LDN prescription, and any 503A-licensed pharmacy may fill it. There is no state-level formulary restriction on compounded medications beyond the federal 503A requirements.

Maryland patients should be aware that 503B outsourcing facilities (which compound without individual prescriptions for office use) operate under different FDA oversight than 503A pharmacies. Most LDN dispensed to individual patients comes through 503A pharmacies, where the prescription is patient-specific.

What to Expect When Starting LDN in Maryland

Most Maryland prescribers initiate LDN at 1.5 mg nightly and titrate to 4.5 mg over 2 to 4 weeks. The gradual titration reduces the incidence of vivid dreams and mild nausea, the two most commonly reported side effects during initiation.

A typical Maryland patient journey: telehealth or in-person consultation ($75 to $200), prescription sent to a 503A pharmacy, first fill of 30 capsules at 1.5 mg ($50), dose adjustment at 2-week follow-up, second fill at target dose. Total first-month cost including the visit: $125 to $250. Ongoing monthly cost after stabilization: $50 for the medication plus $0 to $50 for periodic follow-ups (often quarterly).

Patients taking opioid medications cannot use LDN concurrently due to precipitated withdrawal risk. Maryland prescribers screen for current opioid use before initiating LDN and require a 7 to 14 day washout period from short-acting opioids (longer for extended-release formulations or methadone).

Lab monitoring is not routinely required for LDN, though some prescribers check liver function tests at baseline given naltrexone's hepatotoxicity warning at the 50 mg dose. At 4.5 mg (one-eleventh the standard dose), clinically significant hepatotoxicity has not been reported in published trials [3][6][8].